results suggestive trends for a reduced risk of cancer recurrence were observed with increasing quintiles of daidzein and glycetin intake compared to no intake among postmenopausal women (p for trend: p = .08 for daidzein, p = .06 for glycetin) and among tamoxifen users (p = .10 for daidzein, p = .05 for glycetin).